Showing 15 posts of 78 posts found.


Verona Pharma submits FDA New Drug Application for COPD treatment

June 27, 2023
Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma

UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …


European approval for AstraZeneca’s Trixeo Aerospace in moderate to severe COPD

December 14, 2020
Sales and Marketing AstraZeneca, COPD, EMA, Europe, Trixeo Aerosphere

The European Medicines Agency (EMA) has announced the approval of AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) in the European Union …


AstraZeneca’s triple combination therapy for patients with COPD approved in China

December 23, 2019
Sales and Marketing AstraZeneca, COPD, China, respiration

AstraZeneca has announced that budesonide-glycopyrroniunm-formoterol fumarate has been approved in China for the maintenance treatment of chronic obstructive pulmonary disease …


Living in polluted city for ten years increases risk of lung disease as much as pack of cigarettes a day for 29 years

August 14, 2019
Research and Development Air pollution, COPD, lung disease, pharma emphysema, public health

Air pollution in cities dramatically increases the risk for and risk of progression of emphysema, a form of chronic obstructive …

Breathing life into COPD research

March 21, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COPD, GSK, feature

Alison Hollands, Vice President, Respiratory, UK Pharmaceuticals at GlaxoSmithKline, addresses the importance of implementing the latest approaches to treating COPD …


Mylan’s Wixela becomes first FDA-approved generic version of GSK’s Advair inhaler

January 31, 2019
Sales and Marketing Advair, COPD, FDA, Wixela, asthma, generic, pharma

Mylan’s Wixela has become the first generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder) inhaler to …


Verona’s shares drop 34% on Phase 2 failure of nebulised ensifentrine in COPD

January 15, 2019
Manufacturing and Production, Research and Development Boehringer, COPD, Stiolto Respimat, pharma, trial failure, verona pharma

Verona Pharma has seen its shares crater following the Phase 2 failure of its nebulised ensifentrine, known as RPL554, in …

GSK’s Nucala data insufficient for US COPD approval

September 10, 2018
Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma

GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …


AstraZeneca shocked as inhaler fails to outclass GSK rival in COPD

August 23, 2018
Research and Development AstraZeneca, COPD, GSK, anoro, inhaler, pharma

Researchers at AstraZeneca have been left scratching their heads as new Phase 3b results for its inhaler, Bevespi Aerosphere, posted …

NICE calls to limit antibiotic use in COPD over antimicrobial resistance fears

July 10, 2018
Manufacturing and Production, Medical Communications, Research and Development COPD, NICE, antimicrobial resistance, chronic obstructive pulmonary disease, pharma

NICE have published a draft antimicrobial prescribing guide recommending that healthcare professionals should consider the risk of antimicrobial resistance when …

AZ’s triple therapy inhaler hits 8 out of 9 endpoints

January 26, 2018
Medical Communications, Research and Development AstraZeneca, COPD, biotech, drugs, pharma, pharmaceutical

AstraZeneca has made a brief announcement that its triple therapy inhaler manage to successfully hit eight of nine primary endpoints …

GSK gets EU go-ahead for triple therapy inhaler in COPD

November 16, 2017
Sales and Marketing COPD, FDA, GSK, Trelegy Ellipta, pharma

The EMA has awarded EU marketing authorisation to GlaxoSmithKline and Innovia’s single inhaler triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for …


Non-invasive ventilation touted for COPD treatment at respiratory meeting

September 6, 2016
Manufacturing and Production, Research and Development COPD, resmed

ResMed has presented results at the European Respiratory Society international congress, touting home non-invasive ventilation (NIV) as part of a …


GSK triple combo COPD therapy shows superiority in Phase III trials

June 20, 2016
Research and Development, Sales and Marketing COPD, GSK, phase III

GlaxoSmithKline (LSE: GSK), along with Innoviva (NASDAQ: INVA), have presented positive top-line results from a pivotal Phase III trial for …

GSK says asthma drug Breo shows superior results over standard care in major study

May 24, 2016
Research and Development, Sales and Marketing COPD, GSK, asthma, breo, drug trial

UK drugmaker GlaxoSmithKline (LSE: GSK) on Tuesday said inhaled medicine Breo proved significantly better than standard care in a major …

Latest content